SORRENTO THERAPEUTICS INC (SRNE) Stock Price, Quote, News and Overview
NASDAQ:SRNE - Nasdaq - US83587F2020 - Common Stock - Currency: USD
SRNE Quote, Performance and Key Statistics
0.3073
-0.08 (-20.26%)
The current stock price of SRNE is 0.3073 USD. In the past month the price decreased by -69.57%. In the past year, price decreased by -88.14%.
SRNE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SRNE
Company Profile
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The firm is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.
Company Info
SORRENTO THERAPEUTICS INC
4955 Directors Place
San Diego CALIFORNIA 92121 US
CEO: Henry Ji
Employees: 799
Company Website: https://sorrentotherapeutics.com/
Phone: 18582034100.0
SORRENTO THERAPEUTICS INC / SRNE FAQ
What is the stock price of SORRENTO THERAPEUTICS INC today?
The current stock price of SRNE is 0.3073 USD. The price decreased by -20.26% in the last trading session.
What is the ticker symbol for SORRENTO THERAPEUTICS INC stock?
The exchange symbol of SORRENTO THERAPEUTICS INC is SRNE and it is listed on the Nasdaq exchange.
On which exchange is SRNE stock listed?
SRNE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SORRENTO THERAPEUTICS INC stock?
9 analysts have analysed SRNE and the average price target is 7.82 USD. This implies a price increase of 2444.75% is expected in the next year compared to the current price of 0.3073. Check the SORRENTO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SORRENTO THERAPEUTICS INC worth?
SORRENTO THERAPEUTICS INC (SRNE) has a market capitalization of 145.01M USD. This makes SRNE a Micro Cap stock.
How many employees does SORRENTO THERAPEUTICS INC have?
SORRENTO THERAPEUTICS INC (SRNE) currently has 799 employees.
Is SORRENTO THERAPEUTICS INC (SRNE) expected to grow?
The Revenue of SORRENTO THERAPEUTICS INC (SRNE) is expected to grow by 3.85% in the next year. Check the estimates tab for more information on the SRNE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SORRENTO THERAPEUTICS INC (SRNE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SRNE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SRNE, evaluating the profitability, health, valuation and growth aspects
- SORRENTO THERAPEUTICS INC (SRNE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SORRENTO THERAPEUTICS INC (SRNE) Sales and EPS estimates to see what analysts future expectations are.
- SORRENTO THERAPEUTICS INC (SRNE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SORRENTO THERAPEUTICS INC (SRNE) Insider and Institutional Ownership to learn about the owners and their transactions.
- SORRENTO THERAPEUTICS INC (SRNE) Stock Chart to make your own analysis
- SORRENTO THERAPEUTICS INC (SRNE) Latest news and press-releases to stay up to date.
Does SORRENTO THERAPEUTICS INC (SRNE) stock pay dividends?
SRNE does not pay a dividend.
What is the Price/Earnings (PE) ratio of SORRENTO THERAPEUTICS INC (SRNE)?
SORRENTO THERAPEUTICS INC (SRNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.43).
What is the Short Interest ratio of SORRENTO THERAPEUTICS INC (SRNE) stock?
The outstanding short interest for SORRENTO THERAPEUTICS INC (SRNE) is 0.79% of its float. Check the ownership tab for more information on the SRNE short interest.
SRNE Technical Analysis
SRNE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRNE. SRNE may be in some trouble as it scores bad on both profitability and health.
SRNE Financial Highlights
Over the last trailing twelve months SRNE reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS decreased by -20.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.14 |
SRNE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to SRNE. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 15.83% and a revenue growth 3.85% for SRNE